101
|
Klavins K, Koal T, Dallmann G, Marksteiner J, Kemmler G, Humpel C. The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2015; 1:295-302. [PMID: 26744734 PMCID: PMC4700585 DOI: 10.1016/j.dadm.2015.05.003] [Citation(s) in RCA: 61] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Metabolomic processes have been identified as being strongly linked to the development of Alzheimer's disease (AD). Thus, lipid metabolites appear to be highly useful as diagnostic substrates for the diagnosis of AD and mild cognitive impairment (MCI) in plasma. METHODS We analyzed plasma samples from controls (n = 35), MCI (n = 33), and AD patients (n = 43) using the AbsoluteIDQ p180 Kit (Biocrates Life Sciences), which included quantitative analysis of 40 acylcarnitines, 21 amino acids, 19 biogenic amines, 15 sphingolipids, 90 glycerophospholipids, and sum of hexoses. RESULTS We found that individual lipid metabolites can differentiate controls from MCI and AD with relevant significance. However, the ratio between PC aa C34:4 and lysoPC a C18:2 differentiates controls from MCI (P = .0000007) and from AD (P = .0000009) with greater significance. CONCLUSIONS The results provide evidence that the ratio of these two lipid metabolites is useful for diagnosing MCI and AD with an accuracy of 82%-85%.
Collapse
Affiliation(s)
| | | | | | | | - Georg Kemmler
- Department of Psychiatry and Psychotherapy, University Clinic of General and Social Psychiatry, Medical University of Innsbruck, Innsbruck, Austria
| | - Christian Humpel
- Department of Psychiatry and Psychotherapy, University Clinic of General and Social Psychiatry, Medical University of Innsbruck, Innsbruck, Austria
| |
Collapse
|
102
|
Li N, Liu Y, Li W, Zhou L, Li Q, Wang X, He P. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimer's disease. J Ginseng Res 2015; 40:9-17. [PMID: 26843817 PMCID: PMC4703800 DOI: 10.1016/j.jgr.2015.04.006] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Revised: 04/20/2015] [Accepted: 04/20/2015] [Indexed: 01/10/2023] Open
Abstract
Background Alzheimer's disease (AD) is a progressive brain disease, for which there is no effective drug therapy at present. Ginsenoside Rg1 (G-Rg1) and G-Rg2 have been reported to alleviate memory deterioration. However, the mechanism of their anti-AD effect has not yet been clearly elucidated. Methods Ultra performance liquid chromatography tandem MS (UPLC/MS)-based metabolomics was used to identify metabolites that are differentially expressed in the brains of AD mice with or without ginsenoside treatment. The cognitive function of mice and pathological changes in the brain were also assessed using the Morris water maze (MWM) and immunohistochemistry, respectively. Results The impaired cognitive function and increased hippocampal Aβ deposition in AD mice were ameliorated by G-Rg1 and G-Rg2. In addition, a total of 11 potential biomarkers that are associated with the metabolism of lysophosphatidylcholines (LPCs), hypoxanthine, and sphingolipids were identified in the brains of AD mice and their levels were partly restored after treatment with G-Rg1 and G-Rg2. G-Rg1 and G-Rg2 treatment influenced the levels of hypoxanthine, dihydrosphingosine, hexadecasphinganine, LPC C 16:0, and LPC C 18:0 in AD mice. Additionally, G-Rg1 treatment also influenced the levels of phytosphingosine, LPC C 13:0, LPC C 15:0, LPC C 18:1, and LPC C 18:3 in AD mice. Conclusion These results indicate that the improvements in cognitive function and morphological changes produced by G-Rg1 and G-Rg2 treatment are caused by regulation of related brain metabolic pathways. This will extend our understanding of the mechanisms involved in the effects of G-Rg1 and G-Rg2 on AD.
Collapse
Affiliation(s)
- Naijing Li
- Department of Gerontology, The Shengjing Affiliated Hospital, China Medical University, Shenyang, China
| | - Ying Liu
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Wei Li
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Ling Zhou
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Qing Li
- College of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China
| | - Xueqing Wang
- Department of Gastroenterology, The Shengjing Affiliated Hospital, China Medical University, Shenyang, China
| | - Ping He
- Department of Gerontology, The Shengjing Affiliated Hospital, China Medical University, Shenyang, China
| |
Collapse
|
103
|
González-Domínguez R, García-Barrera T, Vitorica J, Gómez-Ariza JL. High throughput multiorgan metabolomics in the APP/PS1 mouse model of Alzheimer's disease. Electrophoresis 2015; 36:2237-2249. [PMID: 25641566 DOI: 10.1002/elps.201400544] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2014] [Revised: 01/12/2015] [Accepted: 01/13/2015] [Indexed: 12/29/2022]
Abstract
Metabolomics has demonstrated a great potential for the study of pathological mechanisms occurring in brain from Alzheimer's disease patients and transgenic models. However, its application to peripheral samples is not so common, although it can provide interesting information about systemic abnormalities underlying to disease. This work represents the first metabolomic investigation of multiple peripheral organs (liver, kidney, spleen, and thymus) from the APP/PS1 mice by using a high-throughput approach based on direct infusion MS. Our findings demonstrated that these organs suffer significant metabolic impairments related to energy metabolism (e.g. glycolysis, Krebs cycle, β-oxidation), lipid homeostasis (e.g. cellular membrane breakdown and fatty acid metabolism), degradation of nucleotides, oxidative stress, hyperammonemia, and metabolism of amino acids. It is noteworthy that many of these alterations have been previously described in brain, confirming the systemic character of this neurodegenerative disorder and the utility of peripheral samples to understand its pathogenesis.
Collapse
Affiliation(s)
- Raúl González-Domínguez
- Department of Chemistry and CC.MM, Faculty of Experimental Sciences, University of Huelva, Campus de El Carmen, Huelva, Spain.,Campus of Excellence International ceiA3, University of Huelva, Huelva, Spain.,Research Center of Health and Environment (CYSMA), Campus de El Carmen, University of Huelva, Huelva, Spain
| | - Tamara García-Barrera
- Department of Chemistry and CC.MM, Faculty of Experimental Sciences, University of Huelva, Campus de El Carmen, Huelva, Spain.,Campus of Excellence International ceiA3, University of Huelva, Huelva, Spain.,Research Center of Health and Environment (CYSMA), Campus de El Carmen, University of Huelva, Huelva, Spain
| | - Javier Vitorica
- Department Bioquímica, Bromatologia, Toxicología y Medicina Legal, Faculty of Pharmacy, University of Seville, Seville, Spain.,Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Seville, Spain.,Instituto de Biomedicina de Sevilla (IBiS)-Hospital Universitario Virgen del Rocío, CSIC, University of Seville, Seville, Spain
| | - José Luis Gómez-Ariza
- Department of Chemistry and CC.MM, Faculty of Experimental Sciences, University of Huelva, Campus de El Carmen, Huelva, Spain.,Campus of Excellence International ceiA3, University of Huelva, Huelva, Spain.,Research Center of Health and Environment (CYSMA), Campus de El Carmen, University of Huelva, Huelva, Spain
| |
Collapse
|
104
|
Application of metabolomics based on direct mass spectrometry analysis for the elucidation of altered metabolic pathways in serum from the APP/PS1 transgenic model of Alzheimer's disease. J Pharm Biomed Anal 2015; 107:378-85. [DOI: 10.1016/j.jpba.2015.01.025] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2014] [Revised: 01/11/2015] [Accepted: 01/12/2015] [Indexed: 12/17/2022]
|
105
|
Deciphering metabolic abnormalities associated with Alzheimer's disease in the APP/PS1 mouse model using integrated metabolomic approaches. Biochimie 2015; 110:119-128. [DOI: 10.1016/j.biochi.2015.01.005] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2014] [Accepted: 01/05/2015] [Indexed: 01/01/2023]
|
106
|
McIntyre JA, Ramsey CJ, Gitter BD, Saykin AJ, Wagenknecht DR, Hyslop PA. Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease. Autoimmunity 2015; 48:344-51. [PMID: 25672931 PMCID: PMC4490126 DOI: 10.3109/08916934.2015.1008464] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2014] [Revised: 11/24/2014] [Accepted: 01/13/2015] [Indexed: 12/11/2022]
Abstract
A robust blood biomarker is urgently needed to facilitate early prognosis for those at risk for Alzheimer's disease (AD). Redox reactive autoantibodies (R-RAAs) represent a novel family of antibodies detectable only after exposure of cerebrospinal fluid (CSF), serum, plasma or immunoglobulin fractions to oxidizing agents. We have previously reported that R-RAA antiphospholipid antibodies (aPLs) are significantly decreased in the CSF and serum of AD patients compared to healthy controls (HCs). These studies were extended to measure R-RAA aPL in serum samples obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI). Serum samples from the ADNI-1 diagnostic groups from participants with mild cognitive impairment (MCI), AD and HCs were blinded for diagnosis and analyzed for R-RAA aPL by ELISA. Demographics, cognitive data at baseline and yearly follow-up were subsequently provided by ADNI after posting assay data. As observed in CSF, R-RAA aPL in sera from the AD diagnostic group were significantly reduced compared to HC. However, the sera from the MCI population contained significantly elevated R-RAA aPL activity relative to AD patient and/or HC sera. The data presented in this study indicate that R-RAA aPL show promise as a blood biomarker for detection of early AD, and warrant replication in a larger sample. Longitudinal testing of an individual for increases in R-RAA aPL over a previously established baseline may serve as a useful early sero-epidemiologic blood biomarker for individuals at risk for developing dementia of the Alzheimer's type.
Collapse
Affiliation(s)
- John A. McIntyre
- HLA-Vascular Biology Laboratory, Franciscan St. Francis Health, Indianapolis, IN, USA
- Redox-Reactive Reagents, LLC, Indianapolis, IN, USA
| | | | - Bruce D. Gitter
- Department of Oral Biology, Indiana University School of Dentistry, Indianapolis, IN, USA
| | - Andrew J. Saykin
- Department of Radiology and Imaging Sciences, Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Dawn R. Wagenknecht
- HLA-Vascular Biology Laboratory, Franciscan St. Francis Health, Indianapolis, IN, USA
- Redox-Reactive Reagents, LLC, Indianapolis, IN, USA
| | | |
Collapse
|
107
|
Metabolomics reveals significant impairments in the immune system of the APP/PS1 transgenic mice of Alzheimer's disease. Electrophoresis 2015; 36:577-87. [DOI: 10.1002/elps.201400450] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2014] [Revised: 10/10/2014] [Accepted: 10/21/2010] [Indexed: 12/19/2022]
|
108
|
Application of a novel metabolomic approach based on atmospheric pressure photoionization mass spectrometry using flow injection analysis for the study of Alzheimer׳s disease. Talanta 2015; 131:480-9. [DOI: 10.1016/j.talanta.2014.07.075] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2014] [Revised: 07/21/2014] [Accepted: 07/25/2014] [Indexed: 12/14/2022]
|
109
|
Recent Advances and Applications of Metabolomics to Investigate Neurodegenerative Diseases. INTERNATIONAL REVIEW OF NEUROBIOLOGY 2015; 122:95-132. [DOI: 10.1016/bs.irn.2015.05.015] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
110
|
Bujak R, Struck-Lewicka W, Markuszewski MJ, Kaliszan R. Metabolomics for laboratory diagnostics. J Pharm Biomed Anal 2014; 113:108-20. [PMID: 25577715 DOI: 10.1016/j.jpba.2014.12.017] [Citation(s) in RCA: 237] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Revised: 12/08/2014] [Accepted: 12/10/2014] [Indexed: 12/24/2022]
Abstract
Metabolomics is an emerging approach in a systems biology field. Due to continuous development in advanced analytical techniques and in bioinformatics, metabolomics has been extensively applied as a novel, holistic diagnostic tool in clinical and biomedical studies. Metabolome's measurement, as a chemical reflection of a current phenotype of a particular biological system, is nowadays frequently implemented to understand pathophysiological processes involved in disease progression as well as to search for new diagnostic or prognostic biomarkers of various organism's disorders. In this review, we discussed the research strategies and analytical platforms commonly applied in the metabolomics studies. The applications of the metabolomics in laboratory diagnostics in the last 5 years were also reviewed according to the type of biological sample used in the metabolome's analysis. We also discussed some limitations and further improvements which should be considered taking in mind potential applications of metabolomic research and practice.
Collapse
Affiliation(s)
- Renata Bujak
- Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, ul. Gen J. Hallera 107, Gdańsk 80-416, Poland
| | - Wiktoria Struck-Lewicka
- Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, ul. Gen J. Hallera 107, Gdańsk 80-416, Poland
| | - Michał J Markuszewski
- Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, ul. Gen J. Hallera 107, Gdańsk 80-416, Poland.
| | - Roman Kaliszan
- Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, ul. Gen J. Hallera 107, Gdańsk 80-416, Poland.
| |
Collapse
|
111
|
González-Domínguez R, García-Barrera T, Gómez-Ariza JL. Metabolite profiling for the identification of altered metabolic pathways in Alzheimer's disease. J Pharm Biomed Anal 2014; 107:75-81. [PMID: 25575172 DOI: 10.1016/j.jpba.2014.10.010] [Citation(s) in RCA: 137] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2014] [Revised: 10/08/2014] [Accepted: 10/10/2014] [Indexed: 01/05/2023]
Abstract
Gas chromatography coupled to mass spectrometry is the most frequent tool for metabolomic profiling of low molecular weight metabolites. Its suitability in health survey is beyond doubt, given that primary metabolites involved in central pathways of metabolism are usually altered in diseases. The objective of this work is to investigate metabolic differences in serum between Alzheimer's disease patients and healthy controls in order to elucidate pathological mechanisms underlying to disease. Alterations in levels of 23 metabolites were detected, including increased lactic acid, α-ketoglutarate, isocitric acid, glucose, oleic acid, adenosine and cholesterol, as well as decreased urea, valine, aspartic acid, pyroglutamate, glutamine, phenylalanine, asparagine, ornithine, pipecolic acid, histidine, tyrosine, palmitic and uric acid, tryptophan, stearic acid and cystine. Metabolic pathway analysis revealed the involvement of multiple affected pathways, such as energy deficiencies, oxidative stress, hyperammonemia, and others. Moreover, it is noteworthy that some of these compounds have not been previously described in AD research, such as α-ketoglutarate, isocitrate pipecolic acid, pyroglutamate and adenosine, confirming the potential of this metabolomic approach in the search of novel potential markers for early detection of Alzheimer's disease.
Collapse
Affiliation(s)
- Raúl González-Domínguez
- Department of Chemistry and CC.MM, Faculty of Experimental Science, University of Huelva, Campus de El Carmen, 21007 Huelva, Spain; Campus of Excellence International ceiA3, University of Huelva, Spain; Research Center of Health and Environment (CYSMA), University of Huelva, Campus de El Carmen, 21007 Huelva, Spain.
| | - Tamara García-Barrera
- Department of Chemistry and CC.MM, Faculty of Experimental Science, University of Huelva, Campus de El Carmen, 21007 Huelva, Spain; Campus of Excellence International ceiA3, University of Huelva, Spain; Research Center of Health and Environment (CYSMA), University of Huelva, Campus de El Carmen, 21007 Huelva, Spain.
| | - José Luis Gómez-Ariza
- Department of Chemistry and CC.MM, Faculty of Experimental Science, University of Huelva, Campus de El Carmen, 21007 Huelva, Spain; Campus of Excellence International ceiA3, University of Huelva, Spain; Research Center of Health and Environment (CYSMA), University of Huelva, Campus de El Carmen, 21007 Huelva, Spain.
| |
Collapse
|
112
|
Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of Alzheimer's disease. Biochim Biophys Acta Mol Basis Dis 2014; 1842:2395-402. [DOI: 10.1016/j.bbadis.2014.09.014] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2014] [Revised: 09/22/2014] [Accepted: 09/28/2014] [Indexed: 11/21/2022]
|
113
|
González-Domínguez R, Castilla-Quintero R, García-Barrera T, Gómez-Ariza JL. Development of a metabolomic approach based on urine samples and direct infusion mass spectrometry. Anal Biochem 2014; 465:20-7. [DOI: 10.1016/j.ab.2014.07.016] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2014] [Revised: 06/09/2014] [Accepted: 07/16/2014] [Indexed: 01/04/2023]
|
114
|
Metabolomic screening of regional brain alterations in the APP/PS1 transgenic model of Alzheimer's disease by direct infusion mass spectrometry. J Pharm Biomed Anal 2014; 102:425-35. [PMID: 25459942 DOI: 10.1016/j.jpba.2014.10.009] [Citation(s) in RCA: 70] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2014] [Revised: 08/07/2014] [Accepted: 10/09/2014] [Indexed: 12/24/2022]
Abstract
The identification of pathological mechanisms underlying to Alzheimer's disease is of great importance for the discovery of potential markers for diagnosis and disease monitoring. In this study, we investigated regional metabolic alterations in brain from the APP/PS1 mice, a transgenic model that reproduces well some of the neuropathological and cognitive deficits observed in human Alzheimer's disease. For this purpose, hippocampus, cortex, cerebellum and olfactory bulbs were analyzed using a high-throughput metabolomic approach based on direct infusion mass spectrometry. Metabolic fingerprints showed significant differences between transgenic and wild-type mice in all brain tissues, being hippocampus and cortex the most affected regions. Alterations in numerous metabolites were detected including phospholipids, fatty acids, purine and pyrimidine metabolites, acylcarnitines, sterols and amino acids, among others. Furthermore, metabolic pathway analysis revealed important alterations in homeostasis of lipids, energy management, and metabolism of amino acids and nucleotides. Therefore, these findings demonstrate the potential of metabolomic screening and the use of transgenic models for understanding pathogenesis of Alzheimer's disease.
Collapse
|
115
|
González-Domínguez R, García A, García-Barrera T, Barbas C, Gómez-Ariza JL. Metabolomic profiling of serum in the progression of Alzheimer's disease by capillary electrophoresis-mass spectrometry. Electrophoresis 2014; 35:3321-30. [DOI: 10.1002/elps.201400196] [Citation(s) in RCA: 87] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2014] [Revised: 07/27/2014] [Accepted: 08/04/2014] [Indexed: 12/16/2022]
Affiliation(s)
- Raúl González-Domínguez
- Department of Chemistry and CC.MM; Faculty of Experimental Science; University of Huelva; Huelva Spain
- Campus of Excellence International ceiA3; University of Huelva; Spain
- Research Center of Health and Environment (CYSMA); University of Huelva; Huelva Spain
| | - Antonia García
- Center for Metabolomics and Bioanalysis (CEMBIO), Pharmacy Faculty; Universidad San Pablo CEU; Madrid Spain
| | - Tamara García-Barrera
- Department of Chemistry and CC.MM; Faculty of Experimental Science; University of Huelva; Huelva Spain
- Campus of Excellence International ceiA3; University of Huelva; Spain
- Research Center of Health and Environment (CYSMA); University of Huelva; Huelva Spain
| | - Coral Barbas
- Center for Metabolomics and Bioanalysis (CEMBIO), Pharmacy Faculty; Universidad San Pablo CEU; Madrid Spain
| | - José Luis Gómez-Ariza
- Department of Chemistry and CC.MM; Faculty of Experimental Science; University of Huelva; Huelva Spain
- Campus of Excellence International ceiA3; University of Huelva; Spain
- Research Center of Health and Environment (CYSMA); University of Huelva; Huelva Spain
| |
Collapse
|
116
|
Metabolomic study of lipids in serum for biomarker discovery in Alzheimer's disease using direct infusion mass spectrometry. J Pharm Biomed Anal 2014; 98:321-6. [DOI: 10.1016/j.jpba.2014.05.023] [Citation(s) in RCA: 74] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2014] [Revised: 04/12/2014] [Accepted: 05/08/2014] [Indexed: 12/22/2022]
|
117
|
Abstract
Liquid chromatography-mass spectrometry (LC-MS)-based metabolomics can have a major impact in multiple research fields, especially when combined with other technologies, such as stable isotope tracers and genetically modified mice. This review highlights recent applications of metabolomic technology in the study of xenobiotic metabolism and toxicity, and the understanding of disease pathogenesis and therapeutics. Metabolomics has been employed to study metabolism of noscapine, an aryl hydrocarbon receptor antagonist, and to determine the mechanisms of liver toxicities of rifampicin and isoniazid, trichloroethylene, and gemfibrozil. Metabolomics-based insights into the pathogenesis of inflammatory bowel disease, alcohol-induced liver diseases, non-alcoholic steatohepatitis, and farnesoid X receptor signaling pathway-based therapeutic target discovery will also be discussed. Limitations in metabolomics technology such as sample preparation and lack of LC-MS databases and metabolite standards, need to be resolved in order to improve and broaden the application of metabolomic studies.
Collapse
|